NCT06663748

ARX788 in HER2-positive Metastatic Breast Cancer Patients

Evaluate the Efficacy and Safety of ARX788 Given Every 6 Weeks in Patients with HER2-positive Advanced Breast Cancer

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 44 (estimated)
• Sponsor: Henan Cancer Hospital · Other Government
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

A phase 2 study of ARX788 given every 6 weeks in HER2-positive, metastatic breast cancer patients.

Detailed description

A single arm, phase 2 study of ARX788 in HER2-positive, metastatic breast cancer patients. The ARX788 will be administered every 6 weeks (Q6W) intravenous (IV) infusion.

Conditions

• HER2-positive, Metastatic Breast Cancer

Interventions

Type	Name	Description
DRUG	ARX788	2.2 mg/kg IV infusion on Day 1 of each 42-day treatment cycle.

Timeline

• Start date: 2024-11-20
• Primary completion: 2025-11-20
• Completion: 2029-11-20
• First posted: 2024-10-29
• Last updated: 2024-10-29

Regulatory

• FDA-regulated drug study